Related Experiment Video
Updated: Jul 15, 2026
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
SMARCA4 deficiency contributes to platinum resistance in non-small cell lung cancer by activating the
Yufeng Li1, Na Zhou2, Lin Zhang1
1Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background:
SMARCA4-deficient non-small cell lung cancer (NSCLC) is highly aggressive and has a limited response to conventional chemotherapy. The precise mechanisms by which SMARCA4 deficiency contributes to platinum-based chemotherapy resistance in NSCLC remain incompletely understood. This study aims to elucidate this resistance mechanism and provide a theoretical basis for precision treatment in clinical practice.
Methods:
The role of SMARCA4 deficiency in NSCLC was analyzed using the cBioPortal database. SMARCA4-knockdown NSCLC cell models were established. Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8) and colony formation assays. Apoptosis was tested using flow cytometry. Carboplatin (CBP) sensitivity was evaluated by measuring the half maximal inhibitory concentration (IC50) values. Transcriptomic sequencing was performed to screen underlying platinum resistance mechanisms, which were further validated by quantitative polymerase chain reaction (qPCR), Western blot and immunohistochemistry (IHC). Finally, a xenograft model was established to observe the combined antitumor effects of CBP and potential agents reversing drug resistance.
Results:
SMARCA4 deficiency correlated with a poor prognosis for NSCLC patients, and SMARCA4 knockdown promoted malignant phenotypes in NSCLC cell lines. The sensitivity to CBP treatment was attenuated by SMARCA4 downregulation, with concomitant activation of the NF-κB signaling pathway and upregulation of BIRC2 and BIRC3 expression. Bioinformatics analysis confirmed a significant negative correlation between SMARCA4 and BIRC2/BIRC3 messenger RNA (mRNA) expression. Targeted inhibition of NF-κB signaling effectively restored platinum sensitivity in SMARCA4-deficient lung cancer cells and significantly suppressed tumor growth in xenograft models.
Conclusions:
SMARCA4 deficiency contributes to platinum resistance in NSCLC by activating the NF-κB-BIRC2/BIRC3 signaling axis. Combination therapy with CBP and either an NF-κB inhibitor or an inhibitor of apoptosis proteins (IAP) inhibitor effectively reverses this resistance, providing a novel strategy for the precise treatment of SMARCA4-deficient NSCLC.
Insights
SMARCA4-deficient non-small cell lung cancer (NSCLC) shows platinum resistance due to NF-κB pathway activation. Combination therapy targeting this pathway can overcome resistance in NSCLC patients with SMARCA4 deficiency.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- SMARCA4-deficient non-small cell lung cancer (NSCLC) is aggressive with poor chemotherapy response.
- Mechanisms of platinum resistance in SMARCA4-deficient NSCLC are not fully understood.
- This study investigates SMARCA4 deficiency's role in platinum resistance.
Purpose of the Study:
- Elucidate the mechanism of platinum resistance in SMARCA4-deficient NSCLC.
- Identify therapeutic targets for precision treatment.
- Provide a theoretical basis for clinical application.
Main Methods:
- Analyzed SMARCA4 deficiency in NSCLC using cBioPortal.
- Established SMARCA4-knockdown NSCLC cell models.
- Assessed cell proliferation, apoptosis, and carboplatin sensitivity.
- Performed transcriptomic sequencing, qPCR, Western blot, and IHC.
- Utilized xenograft models for in vivo validation.
Main Results:
- SMARCA4 deficiency correlated with poor prognosis and promoted malignant NSCLC phenotypes.
- SMARCA4 downregulation attenuated carboplatin sensitivity via NF-κB pathway activation and BIRC2/BIRC3 upregulation.
- Bioinformatics confirmed negative correlation between SMARCA4 and BIRC2/BIRC3 mRNA.
- NF-κB inhibition restored platinum sensitivity and suppressed tumor growth in vivo.
Conclusions:
- SMARCA4 deficiency drives platinum resistance in NSCLC by activating the NF-κB-BIRC2/BIRC3 axis.
- Combination therapy with carboplatin and NF-κB or IAP inhibitors reverses resistance.
- This presents a novel strategy for treating SMARCA4-deficient NSCLC.
Related Concept Videos
02:23Abnormal Proliferation
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...